Добірка наукової літератури з теми "Brand-name pharmaceutical companies"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Brand-name pharmaceutical companies".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Brand-name pharmaceutical companies"
Silber, Seth, and Kara Kuritz. "Product Switching in the Pharmaceutical Industry: Ripe for Antitrust Scrutiny?" Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 7, no. 2 (April 2010): 119–30. http://dx.doi.org/10.1057/jgm.2010.1.
Повний текст джерелаXie, Jin, and Joseph Gerakos. "The Anticompetitive Effects of Common Ownership: The Case of Paragraph IV Generic Entry." AEA Papers and Proceedings 110 (May 1, 2020): 569–72. http://dx.doi.org/10.1257/pandp.20201029.
Повний текст джерелаXie, Jin. "Horizontal Shareholdings and Paragraph IV Generic Entry in the U.S. Pharmaceutical Industry." Antitrust Bulletin 66, no. 1 (January 11, 2021): 100–112. http://dx.doi.org/10.1177/0003603x20985797.
Повний текст джерелаFullerton, Thomas M., and Steven L. Fullerton. "Aggregate Online Brand Name Pharmacy Price Dynamics for the United States and Mexico." Economies 10, no. 5 (May 12, 2022): 112. http://dx.doi.org/10.3390/economies10050112.
Повний текст джерелаMoken, Merri C. "Fake Pharmaceuticals: How They and Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug Prices." American Journal of Law & Medicine 29, no. 4 (2003): 525–42. http://dx.doi.org/10.1017/s0098858800002598.
Повний текст джерелаBoumil, Marcia M., Emily S. Cutrell, Kathleen E. Lowney, and Harris A. Berman. "Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers." Journal of Law, Medicine & Ethics 40, no. 2 (2012): 311–25. http://dx.doi.org/10.1111/j.1748-720x.2012.00666.x.
Повний текст джерелаRatheesh, R., Bindu Mohandas, and Bhaskaran K. "Evaluation of drug promotional brochures in a tertiary teaching hospital of Kannur, India." International Journal of Basic & Clinical Pharmacology 7, no. 6 (May 22, 2018): 1089. http://dx.doi.org/10.18203/2319-2003.ijbcp20182051.
Повний текст джерелаScheffer, Mario Cesar. "Interaction between pharmaceutical companies and physicians who prescribe antiretroviral drugs for treating AIDS." Sao Paulo Medical Journal 132, no. 1 (2014): 55–60. http://dx.doi.org/10.1590/1516-3180.2014.1321609.
Повний текст джерелаMalik, Salma, Tejus Anantharamu, M. Fadil Salmani, Sapna Pradhan, and A. G. Mathur. "An analysis of adherence to the World Health Organisation guidelines pertaining to drug promotional literature by pharmaceutical firms." International Journal of Basic & Clinical Pharmacology 7, no. 12 (November 24, 2018): 2429. http://dx.doi.org/10.18203/2319-2003.ijbcp20184860.
Повний текст джерелаLexchin, Joel, Sharon Batt, Devorah Goldberg, and Adrienne Shnier. "National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study." BMJ Open 12, no. 3 (March 2022): e055287. http://dx.doi.org/10.1136/bmjopen-2021-055287.
Повний текст джерелаДисертації з теми "Brand-name pharmaceutical companies"
Sun, Wei-Tung, and 孫偉棟. "Patent Litigation Strategy between Generic and Brand Name Pharmaceutical Companies." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/69405015059973402415.
Повний текст джерела國立交通大學
科技法律研究所
102
Pharmaceutical industry is a complex business. While it is without a doubt that researching new drug is a capital-intensive and risky business; however, no all drug makers are engaged in this perilous endeavor. Broadly speaking, generic drug maker is an exception of this trend. By definition, pioneer drug maker, also known as brand name company, are referring to drug maker whose primary mode of business is engaging in researching new drugs; on the other side of the spectrum, is generic drug maker. Generic drug maker are pharmaceutical company that primarily engaged in manufacturing of known drugs whose patent term already expired. From public policy’s perspective, both types of company are useful. Brand name company provides new pharmaceutical innovation and improvement; while generic company facilitates accessibility and provides more economically friendly drug to general public and healthcare provider alike. This conflicting interest will be the main theme throughout this paper and how brand name and generic company use litigation, especially asserting patent right, to further each their own interests i.e. Brand name will want to delay the entrance of generic drug into the market for as long as possible; in contrast, generic drug maker will want to market its drug as soon as possible. This paper will begin by providing an introduction on the history of pharmaceutical industry and its unique characteristics that distinguish this industry from other business. Followed by an introduction on U.S. drug market and some of U.S.’s earlier attempt to control the conflicting interests between brand name and generic drug maker, this paper will start in earnest by providing a critical analysis on Hatch-Waxman Act and patent linkage system that comes with it. The author will comment on some of act’s success and failure and how it opens an era of wild litigation battles between brand name and generic companies. Following Hatch-Waxman Act is another revolutionary piece of legislation known as “Medicare Prescription Drug, Improvement, and Modernization Act” which is American’s attempt to fix problems and abuse created or afforded by Hatch-Waxman Act. As will discuss in detail in this paper, while Medical Moderation Act did successful in eliminating some of the problems that have plagued Hatch-Wax Act for decades, some of its problem remain unresolved and some of act’s half measure inadvertently opens door for more abuses. However, U.S. is certainly not the only country in the world that had become battleground for pharmaceutical companies. This paper will provide a comparison of different regulatory regime implemented by Australia, Canada and Korea to combat these problems. In the latter part of this paper will present some of uniquely Taiwan element that will play a significant role in re-balance the interests. Finally, though Taiwan have yet to fully adopt the American system in controlling drug marketing process, many of the multinational brand name company have already tried their legal tactic used in States in Taiwan’s court. Hopefully, this paper will provide some observation to Taiwan’s court and legislators when or if Taiwan decides to fully implement American system.
Частини книг з теми "Brand-name pharmaceutical companies"
Chorev, Nitsan. "Global Pharmaceuticals and East Africa." In Give and Take, 30–54. Princeton University Press, 2019. http://dx.doi.org/10.23943/princeton/9780691197845.003.0002.
Повний текст джерела